KaloBios Pharmaceuticals, Inc., a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced the sale by Martin Shkreli of his remaining shares of KaloBios common stock, fully eliminating his association with the company. KaloBios also outlined its priority goals as it continues to transform the company. In private transactions, Shkreli sold…
pSivida Announces 13 New Patents Issued or Allowed
pSivida Corp. announced the addition of 13 U.S. and foreign issued patents and allowed applications since the start of 2016. This brings the total number of patents issued and applications allowed in the Company’s intellectual property portfolio to 42 in the U.S. and 191 in foreign jurisdictions. An additional 108 applications are pending in the…
Philadelphia CRO Acquired by Investment Fund
Velocity Fund Partners, a Pittsburgh private equity company, has announced the acquisition of the Philadelphia clinical contract research organization (CRO) Indipharm and is relaunching the CRO as InClinica. Financial terms were not disclosed. Velocity Fund Partners targets promising life sciences opportunities and believes InClinica is well-positioned for growth. “InClinica’s existing global footprint and experience in…
KaloBios Emerges from Chapter 11 Bankruptcy
KaloBios Pharmaceuticals, Inc., a developmental stage biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced that it has emerged from Chapter 11 bankruptcy and has also acquired the rights from Savant Neglected Diseases LLC to develop benznidazole for the treatment of Chagas disease. “The Company has risen from the ashes with…
